XML Sitemap

This is a XML Sitemap which is supposed to be processed by search engines which follow the XML Sitemap standard like Ask.com, Bing, Google and Yahoo.
It was generated using the WordPress content management system and the Google Sitemap Generator Plugin by Arne Brachhold.
You can find more information about XML sitemaps on sitemaps.org and Google's list of sitemap programs.

URLPriorityChange frequencyLast modified (GMT)
https://xconomy.com/boston/2020/03/31/rhythm-pharma-files-drug-application-names-hunter-smith-interim-ceo/60%Monthly2020-03-31 19:51
https://xconomy.com/national/2020/03/31/aptinyx-moves-ahead-with-ptsd-therapy-study-pauses-3-other-trials/60%Monthly2020-03-31 16:45
https://xconomy.com/raleigh-durham/2020/03/31/a-babys-milestones-and-the-next-steps-for-novartis-in-gene-therapy/60%Monthly2020-03-31 16:28
https://xconomy.com/europe/2020/03/31/tapping-into-the-innovation-grid-jj-data-and-a-shifting-healthcare-focus/60%Monthly2020-03-30 22:42
https://xconomy.com/san-diego/2020/03/30/viracta-adds-nordic-nanovectors-lisa-rojkjaer-as-chief-medical-officer/60%Monthly2020-03-30 22:44
https://xconomy.com/san-francisco/2020/03/30/gileads-okazaki-named-assembly-bio-chief-legal-and-business-officer/60%Monthly2020-03-30 21:58
https://xconomy.com/raleigh-durham/2020/03/30/bioventus-ceo-tony-bihl-to-retire-ken-reali-appointed-successor/60%Monthly2020-03-30 21:49
https://xconomy.com/national/2020/03/30/biohavens-acute-migraine-drug-bests-placebo-in-prevention-study/60%Monthly2020-03-30 21:33
https://xconomy.com/new-york/2020/03/30/axsome-plans-to-try-again-after-failure-in-treatment-resistant-depression/60%Monthly2020-03-30 19:01
https://xconomy.com/seattle/2020/03/30/xcelerating-life-sciences-seattle/60%Monthly2020-03-30 15:10
https://xconomy.com/san-diego/2020/03/30/san-diego-biotech-entrepreneurs-innovation-lead-to-maturing-ecosystem/60%Monthly2020-03-30 13:06
https://xconomy.com/europe/2020/03/27/sanofi-adds-mrna-covid-19-vaccine-bet-through-translate-bio-alliance/60%Monthly2020-03-28 01:00
https://xconomy.com/san-diego/2020/03/27/equillium-continues-graft-versus-host-disease-trial-pauses-2-others/60%Monthly2020-03-27 22:12
https://xconomy.com/national/2020/03/27/bio-roundup-clinical-trials-paused-new-ms-drug-kallyopes-cash-more/60%Monthly2020-03-27 15:37
https://xconomy.com/boston/2020/03/26/fusion-pharmaceuticals-taps-james-oleary-as-chief-medical-officer/60%Monthly2020-03-27 12:26
https://xconomy.com/boston/2020/03/26/akcea-therapeutics-promotes-damien-mcdevitt-to-ceo/60%Monthly2020-03-27 12:37
https://xconomy.com/san-diego/2020/03/26/forge-inks-roche-deal-for-antibiotic-aimed-at-drug-resistant-infections/60%Monthly2020-03-27 12:58
https://xconomy.com/san-francisco/2020/03/26/with-80m-recode-looks-to-advance-rna-therapies-for-lung-diseases/60%Monthly2020-03-26 21:55
https://xconomy.com/new-york/2020/03/26/fda-approves-bristol-myers-ms-drug-but-pandemic-will-delay-launch/60%Monthly2020-03-26 14:03
https://xconomy.com/boston/2020/03/26/oncology-needs-combo-therapies-more-data-analysis-says-bio-europe-spring-panel/60%Monthly2020-03-26 07:55
https://xconomy.com/boston/2020/03/25/regenacy-pharma-raises-30m-for-nerve-function-restoring-treatments/60%Monthly2020-03-25 23:08
https://xconomy.com/europe/2020/03/25/astrazeneca-joins-rnai-mix-pledging-80m-to-silence-therapeutics/60%Monthly2020-03-25 19:16
https://xconomy.com/new-york/2020/03/25/kallyope-gains-112m-to-move-gut-brain-axis-programs-to-the-clinic/60%Monthly2020-03-26 00:25
https://xconomy.com/san-francisco/2020/03/24/chrono-therapeutics-top-executive-david-happel-joins-cognoa-as-ceo/60%Monthly2020-03-24 16:54
https://xconomy.com/san-francisco/2020/03/24/cytomx-taps-ex-alder-bio-exec-campoy-as-chief-financial-officer/60%Monthly2020-03-24 18:09
https://xconomy.com/san-francisco/2020/03/24/cytomx-lands-80m-to-kick-off-cancer-drug-rd-pact-with-astellas/60%Monthly2020-03-24 16:58
https://xconomy.com/national/2020/03/24/palforzia-peanut-allergy-immunotherapy-aimmune-ceo-on-rems-manufacturing/60%Monthly2020-03-24 12:55
https://xconomy.com/texas/2020/03/23/genprex-adds-chief-strategy-officer-chief-operating-officer-to-c-suite/60%Monthly2020-03-24 11:42
https://xconomy.com/boston/2020/03/23/epizyme-names-infinitys-jeffery-kutok-as-chief-scientific-officer/60%Monthly2020-03-24 11:38
https://xconomy.com/national/2020/03/23/investors-shaken-by-coronavirus-sow-seeds-of-ma-financing-slowdown/60%Monthly2020-03-24 22:02
https://xconomy.com/europe/2020/03/23/fda-rejects-boehringer-ingelheim-eli-lilly-drug-for-type-1-diabetes/60%Monthly2020-03-23 22:23
https://xconomy.com/boston/2020/03/23/keros-outlines-ipo-plans-amid-markets-rocked-by-coronavirus-pandemic/60%Monthly2020-03-23 18:03
https://xconomy.com/san-francisco/2020/03/23/gsk-veteran-paul-wren-joins-escape-bio-as-chief-scientific-officer/60%Monthly2020-03-23 15:14
https://xconomy.com/boston/2020/03/23/emulate-taps-perkinelmers-corbett-as-ceo-gets-cash-for-commercial-push/60%Monthly2020-03-23 15:00
https://xconomy.com/san-diego/2020/03/20/ucsd-5-diagnostic-makers-partner-to-ramp-covid-19-testing-capacity/60%Monthly2020-03-23 09:06
https://xconomy.com/national/2020/03/20/bio-roundup-coronavirus-diagnostics-therapeutics-vaccines-more/60%Monthly2020-03-20 12:07
https://xconomy.com/san-francisco/2020/03/20/eureka-partners-with-lyell-to-tackle-tricky-solid-tumor-cell-therapies/60%Monthly2020-03-20 09:35
https://xconomy.com/boston/2020/03/19/as-the-commercial-real-estate-market-slumps-look-for-a-more-tenant-friendly-future-2/60%Monthly2020-03-20 12:47
https://xconomy.com/san-diego/2020/03/19/how-san-diego-biotech-leaders-are-adapting-to-coronavirus-concerns/60%Monthly2020-03-30 13:06
https://xconomy.com/national/2020/03/19/fears-of-recession-mount-as-coronavirus-declared-a-pandemic/60%Monthly2020-03-19 11:36
https://xconomy.com/boston/2020/03/18/morphic-appoints-accelerons-peter-linde-as-its-chief-medical-officer/60%Monthly2020-03-18 04:50
https://xconomy.com/national/2020/03/17/abcelleras-coronavirus-neutralizing-antibody-leads-enter-screening/60%Monthly2020-03-18 16:50
https://xconomy.com/national/2020/03/17/qiagen-juices-rna-extraction-kit-capacity-to-feed-coronavirus-test-needs/60%Monthly2020-03-18 07:40
https://xconomy.com/national/2020/03/17/the-benefits-and-impact-of-later-in-licensing-deals-for-biopharma/60%Monthly2020-03-17 10:14
https://xconomy.com/europe/2020/03/16/novo-nordisk-pauses-3-clinical-trials-testing-hemophilia-therapy/60%Monthly2020-03-17 01:06
https://xconomy.com/san-diego/2020/03/14/uc-san-diego-health-develops-covid-19-test-begins-testing-patients/60%Monthly2020-03-16 03:53
https://xconomy.com/national/2020/03/13/lax-approval-requirements-yield-blockbusters-that-dont-work/60%Monthly2020-03-13 16:23
https://xconomy.com/national/2020/03/13/bio-roundup-pandemic-declared-rubius-restarts-kymeras-cash-more/60%Monthly2020-03-13 13:33
https://xconomy.com/boston/2020/03/13/repertoire-immune-taps-torque-top-exec-biogen-vet-john-cox-as-ceo/60%Monthly2020-03-13 07:36
https://xconomy.com/europe/2020/03/13/curevac-founder-ingmar-hoerr-to-replace-ceo-dan-menichella/60%Monthly2020-03-13 07:06
https://xconomy.com/boston/2020/03/12/rubius-drops-rare-diseases-turns-to-cancer-and-autoimmune-disorders/60%Monthly2020-03-13 01:49
https://xconomy.com/boston/2020/03/12/g1s-demaree-jumps-to-karyopharm-for-chief-commercial-officer-job/60%Monthly2020-03-12 20:47
https://xconomy.com/raleigh-durham/2020/03/12/pfizers-gupta-joins-g1-therapeutics-as-chief-commercial-officer/60%Monthly2020-03-13 13:36
https://xconomy.com/boston/2020/03/12/harbour-biomed-tacks-on-75m-to-advance-broad-biologics-pipeline/60%Monthly2020-03-12 18:31
https://xconomy.com/boston/2020/03/12/imara-dives-into-coronavirus-churned-financial-waters-with-a-75m-ipo/60%Monthly2020-03-12 16:59
https://xconomy.com/boston/2020/03/12/kymera-closes-102m-round-to-bring-protein-busting-drugs-to-the-clinic/60%Monthly2020-03-12 19:31
https://xconomy.com/national/2020/03/11/xcelerating-life-sciences-san-diego-will-be-delivered-digitally/60%Monthly2020-03-12 18:44
https://xconomy.com/europe/2020/03/11/with-bristol-and-otsuka-on-board-lsp-raises-620m-eu-life-sciences-fund/60%Monthly2020-03-11 12:35
https://xconomy.com/seattle/2020/03/11/silverback-therapeutics-adds-79m-to-test-her2-tumor-targeting-drug/60%Monthly2020-03-11 12:11
https://xconomy.com/new-york/2020/03/10/genmab-taps-bristol-myers-veteran-mancini-as-chief-operating-officer/60%Monthly2020-03-10 17:20
https://xconomy.com/san-francisco/2020/03/10/ngm-bios-trombley-to-step-down-to-become-ceo-of-unnamed-company/60%Monthly2020-03-11 06:03
https://xconomy.com/boston/2020/03/10/acceleron-drops-drug-for-rare-muscle-disease-after-mixed-phase-2-data/60%Monthly2020-03-10 13:31
https://xconomy.com/boston/2020/03/09/kala-to-take-another-shot-at-fda-approval-with-new-dry-eye-drug-data/60%Monthly2020-03-10 00:14
https://xconomy.com/europe/2020/03/09/cushings-disease-drug-that-novartis-sold-to-recordati-nabs-fda-nod/60%Monthly2020-03-09 20:36
https://xconomy.com/new-york/2020/03/09/zentalis-leads-a-trio-of-biotechs-charting-a-course-for-wall-street/60%Monthly2020-03-09 17:20
https://xconomy.com/san-francisco/2020/03/06/senti-biosciences-appoints-jose-iglesias-as-its-chief-medical-officer/60%Monthly2020-03-06 22:41
https://xconomy.com/national/2020/03/06/bio-roundup-gileads-4-9b-deal-covid-19-collabs-ipo-plans-more/60%Monthly2020-03-06 23:08
https://xconomy.com/san-diego/2020/03/05/roche-trial-of-ionis-huntingtons-disease-drug-halted-after-side-effects/60%Monthly2020-03-06 12:43
https://xconomy.com/national/2020/03/05/macrogenics-chief-medical-officer-jon-wigginton-announces-resignation/60%Monthly2020-03-05 19:58
https://xconomy.com/europe/2020/03/05/psioxus-therapeutics-appoints-tom-lillie-as-chief-medical-officer/60%Monthly2020-03-05 19:44
https://xconomy.com/san-francisco/2020/03/05/culture-biosciences-raises-15m-to-expand-bioreactor-capacity/60%Monthly2020-03-05 19:14
https://xconomy.com/new-york/2020/03/04/melintas-chapter-11-auction-draws-no-bids-deerfield-to-get-assets/60%Monthly2020-03-05 00:36
https://xconomy.com/san-francisco/2020/03/04/amunix-raises-73m-to-bring-safer-t-cell-engagers-to-solid-tumors/60%Monthly2020-03-04 19:34
https://xconomy.com/boston/2020/03/04/amag-pharma-chief-medical-officer-julie-krop-to-step-down/60%Monthly2020-03-04 16:26
https://xconomy.com/boston/2020/03/04/bluerock-hires-former-unum-exec-ettenberg-as-chief-scientific-officer/60%Monthly2020-03-04 16:16
https://xconomy.com/national/2020/03/04/court-rules-more-trial-data-must-be-posted-on-clinicaltrials-gov/60%Monthly2020-03-03 14:14
https://xconomy.com/san-francisco/2020/03/03/novartis-leads-100m-round-for-fibrosis-focused-pliant-therapeutics/60%Monthly2020-03-03 22:27
https://xconomy.com/national/2020/03/03/sanofi-wins-fda-nod-for-combo-therapy-in-multiple-myeloma/60%Monthly2020-03-03 21:19
https://xconomy.com/san-francisco/2020/03/03/biogens-anirvan-ghosh-to-succeed-keith-leonard-as-unity-bio-ceo/60%Monthly2020-03-03 15:22
https://xconomy.com/europe/2020/03/03/oculis-taps-shire-veteran-de-souza-lima-as-chief-medical-officer/60%Monthly2020-03-03 15:11
https://xconomy.com/national/2020/03/03/national-xconomy-awards-now-accepting-nominations-for-the-best-in-biotech/60%Monthly2020-03-03 13:31
https://xconomy.com/san-francisco/2020/03/02/gilead-boosts-cancer-drug-pipeline-with-4-9b-deal-for-forty-seven/60%Monthly2020-03-03 03:37
https://xconomy.com/san-francisco/2020/03/02/oric-pharma-plans-ipo-to-test-therapies-for-drug-resistant-cancers/60%Monthly2020-03-02 22:18
https://xconomy.com/national/2020/03/02/2020-national-xconomy-awards/60%Monthly2020-04-02 16:22
https://xconomy.com/boston/2020/03/02/xilio-unveils-new-name-100m-to-bring-targeted-cancer-drugs-to-clinic/60%Monthly2020-03-03 19:13